No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 25,986 | 32,375 | 37,649 | 45,119 | 45,064 | 44,816 | 53,656 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 3,354 | 5,495 | 4,128 | 5,166 | 4,053 | 5,015 | 5,950 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Similar companies
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- The United Laboratories International Holdings Limited
- Eris Lifesciences Limited
- Fujian Cosunter Pharmaceutical Co., Ltd.
- AstraZeneca Pharma India Limited
- Shanghai Haoyuan Chemexpress Co., Ltd.
- Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
- Dermapharm Holding SE
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Granules India Limited (GRANULES.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- The United Laboratories International Holdings Limited
- Eris Lifesciences Limited
- Fujian Cosunter Pharmaceutical Co., Ltd.
- AstraZeneca Pharma India Limited
- Shanghai Haoyuan Chemexpress Co., Ltd.
- Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
- Dermapharm Holding SE